

**Pharmacy and Therapeutics Committee Meeting
Agenda**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
April 29, 2010 - 10:00 a.m.*

DRAFT AGENDA

Welcome and Comments	Cindi B. Jones, Acting DMAS Director
Call to Order	Randy Axelrod, M.D., Chairman
Approval of Minutes from February 9, 2010 Meeting	P&T Committee Members
PDL Management	P&T Committee Members

- ◆ **Old Business**
 - Multiple Sclerosis Agents Class Review (*Immunologic Agents*)
 - Self Administered Drugs for Rheumatoid Arthritis Class Review(*Immunologic Agents*)
 - Thiazolidinediones Class Review (*Endocrine and Metabolic Agents*)
 - Prior Authorization Fax Form for Long-Acting Narcotics
 - Prior Authorization Fax Form for Platelet Inhibitors (i.e., prasugrel)
- ◆ **Potential New PDL Category Review**
 - Cough and Cold Agents
- ◆ **PDL Phase I – New Drug Review (*Therapeutic Class*)**
 - AdrenaClick® (*Self-injectable Epinephrine*)
 - Allegra®-D 12 hour (*Antihistamines – 2nd generation*)
 - Nizatidine Suspension (*Histamine₂ Receptor Antagonist*)
 - Perindopril (*Angiotensin Converting Enzyme Inhibitor*)
 - Welchol® packets (*Lipotropics: Bile Acid Sequestrant*)
- ◆ **PDL Phase II – New Drug Review (*Therapeutic Class*)**
 - TBA
- ◆ **Potential New Therapeutic Class Review (*PDL Category*)**
 - Contraceptives - oral, non-oral, injectable (*Endocrine and Metabolic Agents*)
 - Estrogens - vaginal (*Endocrine and Metabolic Agents*)
 - GI Stimulant (*Gastrointestinal*)
 - Incretin Mimetics (*Endocrine and Metabolic Agents*)
 - Neuromuscular Blocker Agents (*Central Nervous System*)
 - Pancreatic Enzymes (*Gastrointestinal*)
 - Scabidicals / Pediculocides (*Dermatologic*)
 - Short Acting Analgesics including combination drugs (*Analgesics*)
 - Skeletal Muscle Relaxants (*Central Nervous System*)
 - Smoking Cessation Aids (*Central Nervous System*)
- ◆ **Potential New Therapeutic Class Review (*PDL Category*) Subject to General Assembly Approval**
 - Atypical Antipsychotics* (*Central Nervous System*)
 - Serotonin Norepinephrine Reuptake Inhibitors* (SNRIs) (*Central Nervous System*)
 - Selective Serotonin Reuptake Inhibitors (SSRIs)* (*Central Nervous System*)

*Subject to final actions of the 2010 Virginia General Assembly

Confidential Meeting

◆ **Pricing Information Discussion**

**P&T Committee Members, DMAS, and
FHSC Pursuant to 42 U.S.C. § 1396r-8**

Criteria Discussion of Potentially New Classes**

P&T Committee Members

Criteria Discussion of Phase I New Drugs**

P&T Committee Members

Criteria Discussion of Phase II New Drugs**

P&T Committee Members

Next Meeting – October 21, 2010

Randy Axelrod, M.D., Chairman

***Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II which are scheduled for review at the April meeting, potential new drug classes, and specific new drugs in PDL Phase I and II classes listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- New Drugs in PDL Phase I or II Drug Classes – April 2009 to present
- Potential New Drug Classes – April 2008 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov **by close of business Friday, April 1, 2010.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov **by close of business Friday, April 1, 2010.**